

**Listing of the Claims:**

1. (Currently Amended) A composition which comprises:
  - (a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a converted ceramide portion, which differs from a ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;
  - (b) QS-21; and
  - (c) a pharmaceutically acceptable carrier,wherein the conjugate and QS-21 are each present in the composition in an amount effective to stimulate or enhance antibody production in a subject ~~and the composition is lyophilized.~~
- 2.-5. (Canceled)
6. (Previously Presented) The composition of claim 1, wherein the amount of the conjugate is between about 3 µg and about 100 µg.
7. (Previously Presented) The composition of claim 1, wherein the amount of QS-21 is between about 30

µg and about 100 µg.

8. (Previously Presented) The composition of claim 1, wherein the subject is a human.

9.-10. (Canceled)

11. (Currently Amended) A method of enhancing antibody production in a subject which comprises administering to the subject an effective antibody producing amount of a composition comprising:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a converted ceramide portion, which differs from a ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier, wherein the conjugate and QS-21 are each present in the composition in an amount effective to stimulate or enhance antibody production in a subject ~~and the composition is lyophilized.~~

12.-13. (Cancelled)

14. (Currently Amended) A method of treating a small cell lung cancer in a subject which comprises administering to the subject an effective small cell lung cancer treating amount of a composition comprising:

- \_\_\_\_\_ (a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a converted ceramide portion, which differs from a ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;
- (b) QS-21; and
- (c) a pharmaceutically acceptable carrier, wherein the conjugate and QS-21 are each present in the composition in an amount effective to treat the small cell lung cancer in the subject ~~and the composition is lyophilized.~~

15.-16. (Canceled)